Acyl-CoA dehydrogenase deficiency

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:309120
Who is this for?
Show terms as
3Active trials11Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Acyl-CoA dehydrogenase deficiency (also sometimes referred to by its specific subtype names, such as SCAD, MCAD, LCAD, or VLCAD deficiency, depending on which enzyme is affected) is a group of inherited metabolic disorders. These conditions affect the body's ability to break down certain fats and turn them into energy. Normally, when your body needs fuel — especially during fasting, illness, or exercise — it breaks down stored fat. In acyl-CoA dehydrogenase deficiency, a key enzyme in this process is missing or not working properly, so the body cannot complete this step. This causes a buildup of harmful fatty substances and a shortage of energy, particularly affecting the heart, muscles, liver, and brain. Symptoms can range widely depending on which specific enzyme is affected. Common problems include low blood sugar (hypoglycemia), extreme tiredness, muscle weakness, and in some cases, serious heart problems. Some people may have no symptoms until a period of stress like an illness triggers a metabolic crisis. The most common subtype, MCAD deficiency, is now detected through newborn screening in many countries, which has greatly improved outcomes. Treatment focuses on preventing metabolic crises by avoiding long periods without eating, following a carefully managed diet, and sometimes taking supplements like riboflavin (vitamin B2) or carnitine. With early diagnosis and proper management, many people with this condition live healthy, relatively normal lives. However, without treatment, severe episodes can be life-threatening.

Key symptoms:

Low blood sugar (hypoglycemia), especially during fasting or illnessExtreme tiredness or lack of energyMuscle weakness or painVomiting, particularly during illnessLiver enlargementHeart muscle problems (cardiomyopathy) in some subtypesDevelopmental delays in some childrenSeizures during metabolic crisesBreathing difficulties during acute episodesPoor feeding in newbornsIrritability or unusual behavior during low blood sugar episodesMuscle breakdown (rhabdomyolysis) in some subtypes

Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

3 events
Jul 2026Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

Jerry Vockley, MD, PhD — PHASE2

TrialRECRUITING
Jun 2025Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

Jerry Vockley, MD, PhD — PHASE2

TrialRECRUITING
Oct 2024Metabolic Effects of Medium-Chain Fatty Acids in Patients With Medium-Chain Acyl-CoA Dehydrogenase Deficiency and Healthy Individuals

University of Copenhagen — NA

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Acyl-CoA dehydrogenase deficiency.

3 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

3 recruitingView all trials with filters →
Phase 22 trials
Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
Phase 2
Actively Recruiting
PI: Gerard Vockley (UPMC Children's Hospital of Pittsburgh) · Sites: Pittsburgh, Pennsylvania · Age: 499 yrs
Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
Phase 2
Actively Recruiting
PI: Gerard Vockley, MD, PhD (UPMC Children's Hospital of Pittsburgh) · Sites: Pittsburgh, Pennsylvania · Age: 499 yrs
N/A1 trial
Metabolic Effects of Medium-Chain Fatty Acids in Patients With Medium-Chain Acyl-CoA Dehydrogenase Deficiency and Healthy Individuals
N/A
Actively Recruiting
PI: Andreas M Fritzen, Associate Professor (University of Copenhagen) · Sites: Copenhagen · Age: 1880 yrs

Specialists

11 foundView all specialists →
SC
Soon P Chee
Specialist
PI on 1 active trial7 Acyl-CoA dehydrogenase deficiency publications
PM
Paul AH Moss, PhD MRCP MRCPath
WILLSBORO, NY
Specialist
PI on 1 active trial
NF
Nicholas J Cowley, MBChB MRCP FRCA
SPOKANE, WA
Specialist
PI on 1 active trial
JF
Julian F Bion, MD FRCP FRCA
Specialist
PI on 1 active trial
SM
Simone T Yabiku, MD
Specialist
PI on 1 active trial
GV
Gerard L Vockley
PITTSBURGH, PA
Specialist
PI on 1 active trial
TD
Terry Derks
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Acyl-CoA dehydrogenase deficiency.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Acyl-CoA dehydrogenase deficiencyForum →

No community posts yet. Be the first to share your experience with Acyl-CoA dehydrogenase deficiency.

Start the conversation →

Latest news about Acyl-CoA dehydrogenase deficiency

Disease timeline:

New recruiting trial: Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

A new clinical trial is recruiting patients for Acyl-CoA dehydrogenase deficiency

New recruiting trial: Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

A new clinical trial is recruiting patients for Acyl-CoA dehydrogenase deficiency

New recruiting trial: Metabolic Effects of Medium-Chain Fatty Acids in Patients With Medium-Chain Acyl-CoA Dehydrogenase Deficiency and Healthy Individuals

A new clinical trial is recruiting patients for Acyl-CoA dehydrogenase deficiency

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Which specific subtype of acyl-CoA dehydrogenase deficiency does my child have, and how does that affect their treatment plan?,What is our emergency protocol if my child becomes ill and cannot eat?,How long can my child safely go without eating at different ages?,Does my child need any dietary restrictions, and should we see a metabolic dietitian?,Should other family members, including siblings, be tested for this condition?,Are there any activities or sports my child should avoid?,What should I tell the school, emergency room, or any doctor who does not know about this condition?

Common questions about Acyl-CoA dehydrogenase deficiency

What is Acyl-CoA dehydrogenase deficiency?

Acyl-CoA dehydrogenase deficiency (also sometimes referred to by its specific subtype names, such as SCAD, MCAD, LCAD, or VLCAD deficiency, depending on which enzyme is affected) is a group of inherited metabolic disorders. These conditions affect the body's ability to break down certain fats and turn them into energy. Normally, when your body needs fuel — especially during fasting, illness, or exercise — it breaks down stored fat. In acyl-CoA dehydrogenase deficiency, a key enzyme in this process is missing or not working properly, so the body cannot complete this step. This causes a buildup

How is Acyl-CoA dehydrogenase deficiency inherited?

Acyl-CoA dehydrogenase deficiency follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for Acyl-CoA dehydrogenase deficiency?

Yes — 3 recruiting clinical trials are currently listed for Acyl-CoA dehydrogenase deficiency on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Acyl-CoA dehydrogenase deficiency?

11 specialists and care centers treating Acyl-CoA dehydrogenase deficiency are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.